Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development

4 Jun 2020

Abstract excerpt

Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. It develops mainly via NE transdifferentiation of prostate adenocarcinoma in response to androgen receptor (AR)-inhibition therapy. The study of NEPC development has been hampered by a lack of clinically relevant models. We previously established a unique and first-in-field patient-derived xenograft (PDX) model of adenocarcinoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hippo pathway signaling and YAP/TAZ
Share to Prostate Cancer Treatment and Research
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32512818
DOI: 10.3390/cells9061398

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer DevelopmentPMID 32512818Read ↗

Conditionally reprogrammed normal and primary tumor prostate epithelial cells: a novel patient-derived cell model for studies of human prostate cancer.Semantic proximity Read ↗

Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1Semantic proximity Read ↗

The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1Semantic proximity Read ↗

The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1Semantic proximity Read ↗

Longitudinal single-cell RNA sequencing of a neuroendocrine transdifferentiation model reveals transcriptional reprogramming in treatment-induced neuroendocrine prostate cancerSemantic proximity Read ↗

Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant modelSemantic proximity Read ↗

Patient derived organoids to model rare prostate cancer phenotypes.Semantic proximity Read ↗

Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4Semantic proximity Read ↗

A modular patient-derived organoid–xenograft platform reveals molecular and clinical trajectories of prostate cancer progressionSemantic proximity Read ↗

Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factorsSemantic proximity Read ↗

Establishment and characterization of a novel treatment‐related neuroendocrine prostate cancer cell line KUCaP13Semantic proximity Read ↗

Longitudinal single-cell profiling links RUNX1T1 to lineage transition and maintenance in treatment-induced neuroendocrine prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.